Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy.

Trial Details

NCT ID
NCT06276868
Phase
PHASE2
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Dalcilib+letrozole+HP treatment group
Locations (sample)
  • Henan, Henan, China|33.81876,112.13664

Key Eligibility Criteria

  • Female initial treatment patients aged ≥ 18 years and ≤ 70 years.
  • ECOG score 0-1 points.
  • Pathologically confirmed as invasive breast cancer, with tumor staging of II-IIIA.
  • HR positive HER-2 positive.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →